Journals / Anadolu Kardiyoloji Dergisi / 2012 / Cilt: 12 - Sayı: 2

İskemik dilate kardiyomiyopatide kardiyak resenkronizasyon yanıtlarına miyokart canlılığının etkisi: Bir prospektif gözlemsel kohort çalışması

Influence of myocardial viability on responsiveness to cardiac resynchronization in ischemic dilated cardiomyopathy: A prospective observational cohort study

Pages
132–141
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The maximum difference of the decrease of left ventricular volumes between the two groups occurred after the first week (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To understand whether patients with post-ischemic dilated cardiomyopathy and myocardial viability (MV) could benefit from cardiac resynchronization therapy (CRT) in terms of clinical, echocardiographic and neuro- hormonal parameters compared to patients without MV.
📊
Key Findings & Data:Using dobutamine stress echocardiography, 2 groups were identified: group A of 51 patients with MV and group B of 53 patients without MV.
💡
Conclusion & Impact:The maximum difference of the decrease of left ventricular volumes between the two groups occurred after the first week (p
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To understand whether patients with post-ischemic dilated cardiomyopathy and myocardial viability (MV) could benefit from cardiac resynchronization therapy (CRT) in terms of clinical, echocardiographic and neuro- hormonal parameters compared to patients without MV. Methods: One hundred and four consecutive patients were enrolled in a prospective observational cohort study. Using dobutamine stress echocardiography, 2 groups were identified: group A of 51 patients with MV and group B of 53 patients without MV. All patients were implanted with biventricular pacing devices combined with an internal cardioverter-defibrillator. Clinical, echocardiographic and neuro-hormonal param- eters were evaluated at baseline and at six month follow-up. Analysis of variance for repeated measures on each variable suggestive of remod- eling was performed. We considered responder every patient with: decrease of > 15% in left ventricular volumes and/or improvement in left ventricular ejection fraction of > 5% in addition to NYHA class improvement. Results: All the variables improved in both groups (time effect). Comparing the two groups (group effect), the following variables were signifi- cantly better in group A: N-terminal pro-B-type natriuretic peptide (p=0.02), NYHA class (p=0.003), reverse remodeling (RR) (p=0.007), dP/dt (p=0.005), left ventricular ejection fraction (p=0.009), 3rd sound (p=0.01), and left ventricular end-systolic volume after the first week (p=0.035). RR occurred at the first week after CRT only in Group A and was maintained for all the time of this study. The maximum difference of the decrease of left ventricular volumes between the two groups occurred after the first week (p

Özet

Amaç: Post-iskemik dilate kardiyomiyopatili ve miyokart canlılığı (MV) olan hastaların, klinik, ekokardiyografik ve nöro-hormonal parametreler açısından, MV olmayan hastalarla karşılaştırıldığında kardiyak resenkronizasyon tedavisinden (KRT) yarar görüp-görmeyeceklerini anlamak. Yöntemler: Prospektif, gözlemsel kohort çalışmaya 104 ardışık hasta dahil edildi. Dobutamin stres ekokardiyografi kullanarak, 2 grup tespit edildi: A grup 51 MV’li hasta ve grup B 53 MV’siz hasta. Tüm hastalara internal kardiyoverter-defibrilatörle kombine biventriküler pacing cihazı konuldu. Klinik olarak, ekokardiyografik ve nöro-hormonal parametreler başlangıç ve altı aylık takipte değerlendirildi. Remodeling düşündüren her değişken hakkında tekrarlayan ölçümler için varyans analizi yapıldı. Aşağıdakileri olan her hasta “cevap veren” olarak düşünüldü: NYHA sınıflamasında düzelmeye ilaveten, sol ventrikül völümlerinde > %15 azalma ve/veya sol ventrikül ejeksiyon fraksiyonunda > %15 düzelme. Bulgular: Tüm değişkenler her iki grupta da (zaman etkisi) düzeldi. İki grup karşılaştırıldığında (grup etkisi), aşağıdaki değişkenler A grubunda anlamlı olarak daha iyi: N-terminal pro-B-tip natriüretik peptid (p=0.02), NYHA sınıf (p=0.003), tersine remodeling (TR) (p=0.007), dP/dt (p=0.005), sol ventrikül ejeksiyon fraksiyonu (p=0.009), 3. ses (p=0.01) ve ilk haftadan sonra sol ventrikül sistol sonu völümü (p=0.035). Tersine remodeling KRT’den sonra ilk haftada sadece A grubunda meydana geldi ve bu çalışmanın tüm süresinde devam etti. İlk haftadan sonra, iki grup arasında maksimum SVSSV’de azalma farkı oluştu (p

🔖

Cite This Article

GIROLAMO, P. D., VITALI, A., NATALE, E., LEGGIO, M., CHIARELLI, A., PAPPALARDO, A., AVELLA, A., LAURENZI, F., MINARDI, G., ZAMPI, G., PUGLIESE, M., FERA, M. S. (2022). İskemik dilate kardiyomiyopatide kardiyak resenkronizasyon yanıtlarına miyokart canlılığının etkisi: Bir prospektif gözlemsel kohort çalışması. Anadolu Kardiyoloji Dergisi, Cilt: 12 - Sayı: 2, 132–141. https://ajindex.com/articles/436333

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-25
  2. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133: 703-12. [CrossRef] 3. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 1997; 30: 1589-97. [CrossRef] 4. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update: ACC/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2005 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016. [CrossRef] 5. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-442. [CrossRef] 6. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail 2000; 6: 276-85. [CrossRef] 7. Linde C, Leclercq C, Rex S, Garrigue S, Lavergne T, Cazeau S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002; 40: 111-8. [CrossRef] 8. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al. Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289: 2685-94. [CrossRef] 9. Cleland